• +1-646-491-9876
    • +91-20-67278686

    Search

    Tumor Necrosis Factor Receptor Superfamily Member 10A Pipeline Review H1 2017

    Tumor Necrosis Factor Receptor Superfamily Member 10A Pipeline Review H1 2017

    • Report Code ID: RW0001858683
    • Category Pharmaceuticals
    • No. of Pages 50
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Pipeline Review, H1 2017

    Summary

    Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A) or Death receptor 4 (DR4) is a protein encoded by TNFRSF10A. This receptor is activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL) , and thus transduces cell death signal and induces cell apoptosis. It promotes the activation of NF-kappa-B.

    Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) pipeline Target constitutes close to 10 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively. Report covers products from therapy areas Oncology which include indications Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) , Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) , Colorectal Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Lymphoma, Multiple Myeloma (Kahler Disease) , Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma and Solid Tumor.

    The latest report Tumor Necrosis Factor Receptor Superfamily Member 10A - Pipeline Review, H1 2017, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type. It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A)
    - The report reviews Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Overview
    Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Companies Involved in Therapeutics Development
    AbbVie Inc
    Galaxy Biotech LLC
    GlaxoSmithKline Plc
    Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Drug Profiles
    ABBV-621 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AY-4 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Biologic to Agonize TRAIL Receptor 1 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CD19L-sTRAIL - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dulanermin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HuD-114 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HuYON-007 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    M-921 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    mapatumumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Dormant Products
    Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Discontinued Products
    Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Product Development Milestones
    Featured News & Press Releases
    Apr 11, 2017: Apogenix Announces Initiation of Clinical Development for ABBV-621 to Treat Solid and Hematologic Tumors by Partner AbbVie
    Jun 09, 2010: Human Genome Sciences Announces Results Of Phase II Trial Of Mapatumumab In Multiple Myeloma
    Mar 17, 2010: Human Genome Sciences Announces Results of Randomized Phase II Trial of Mapatumumab in Non-Small Cell Lung Cancer
    Dec 20, 2008: Human Genome Sciences Initiates Second Randomized Phase II Trial Of HGS-ETR1 In Combination With Chemotherapy
    Sep 02, 2008: Human Genome Sciences Reports Initial Results Of Randomized Phase II Trial Of HGS-ETR1 In Combination With Bortezomib In Advanced Multiple Myeloma
    Aug 22, 2008: Human Genome Sciences Completes Enrollment In Randomized Phase II Trial Of HGS-ETR1 In Non-Small Cell Lung Cancer
    Oct 24, 2007: Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trial Receptor Antibodies In Combination With Chemotherapy
    Jul 20, 2006: Human Genome Sciences Initiates Randomized Phase II Clinical Trial Of HGS-ETR1 In Combination With Bortezomib
    Dec 13, 2005: Human Genome Sciences Reports Results Of Phase 2 Clinical Trial Of HGS-ETR1 In Patients With Advanced Non-Hodgkin's Lymphoma
    Nov 01, 2005: Human Genome Sciences Reports Results Of Phase 2 Clinical Trial Of HGS-ETR1 In Patients With Advanced Colorectal Cancer
    Aug 18, 2005: Glaxosmithkline Exercises Option To Human Genome Sciences' Trial Receptor Antibody
    Jul 05, 2005: Human Genome Sciences Reports Results Of Phase II Clinical Trial Of HGS-ETR1 In Patients With Non-Small Cell Lung Cancer
    Jun 13, 2005: Human Genome Sciences Reports Interim Results Of Phase II Clinical Trial Of HGS-ETR1 In Patients With Advanced Non-Hodgkin's Lymphoma
    May 17, 2005: Human Genome Sciences Reports Results Of Phase I Clinical Trials Of HGS-ETR2 And HGS-ETR1 In Patients With Advanced Solid Tumors
    Apr 18, 2005: Human Genome Sciences Reports Results Of Phase 1 Clinical Trial Of HGS-ER1 In Patients With Advanced Solid Tumors
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indication, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by AbbVie Inc, H1 2017
    Pipeline by Galaxy Biotech LLC, H1 2017
    Pipeline by GlaxoSmithKline Plc, H1 2017
    Dormant Projects, H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    AbbVie Inc
    Galaxy Biotech LLC
    GlaxoSmithKline Plc

    Request for Sample

    Report Url https://www.reportsweb.com//tumor-necrosis-factor-receptor-superfamily-member-10a-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//tumor-necrosis-factor-receptor-superfamily-member-10a-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//tumor-necrosis-factor-receptor-superfamily-member-10a-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments